Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 3, 2015, Pages e96-

  Ramanathan, Sudarshini ^a,b,c   Langguth, Daman ^d   Hardy, Todd A ^a,e   Garg, Nidhi ^a   Bundell, Chris ^f,g   Rojana Udomsart, Arada ^g   Dale, Russell C ^b   Robertson, Thomas ^h   Mammen, Andrew L ⁱ   Reddel, Stephen W ^a,e  

^a Department of Geriatric Medicine   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WESTMEAD HOSPITAL   (Australia)

^d SULLIVAN NICOLAIDES PATHOLOGY   (Australia)

^e University of Sydney   (Australia)

^f PATHWEST LABORATORY MEDICINE   (Australia)

^g UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^h ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

ⁱ NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; AUTOANTIBODY; AZATHIOPRINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; IMMUNOGLOBULIN; METHOTREXATE; PREDNISONE; RITUXIMAB; STEROID;

ADULT; AGED; ARTICLE; AUSTRALIAN; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG WITHDRAWAL; ELECTROMYOGRAM; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MALE; MIDDLE AGED; MUSCLE BIOPSY; MUSCLE NECROSIS; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYOSITIS; NECROTIZING AUTOIMMUNE MYOPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; RELAPSE; REMISSION; STEROID THERAPY;

EID: 85021023342     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000096     Document Type: Article

References (14)

1. Radcliffe KA, Campbell WW. Statin myopathy. Curr Neurol Neurosci Rep 2008;8:66-72.
2. van der Most PJ, Dolga AM, Nijholt IM, Luiten PGM, Eisel ULM. Statins: mechanisms of neuroprotection. Prog Neurobiol 2009;88:64-75.
3. Sirtori CR, Mombelli G, Triolo M, Laaksonen R. Clinical response to statins: mechanism(s) of variable activity and adverse effects. Ann Med 2012;44:419-432.
4. Bellosta S, Corsini A. Statin drug interactions and related adverse reactions. Expert Opin Drug Saf 2012;11:933-946.
5. Dimachkie MM. Idiopathic inflammatory myopathies. J Neuroimmunol 2011;231:32-42.
6. Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 2011;7: 343-354.
7. Liang C, Needham M. Necrotizing autoimmune myopa-thy. Curr Opin Rheumatol 2011;23:612-619.
8. Grable-Esposito P, Katzberg HD, Greenberg SA, Srinivasan J, Katz J, Amato AA. Immune-mediated necro-tizing myopathy associated with statins. Muscle Nerve 2010;41:185-190.
9. Christopher-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 2010;62:2757-2766.
10. Mammen AL, Chung T, Christopher-Stine L, et al. Auto-antibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 2011;63:713-721.
11. Mammen AL, Pak K, Williams EK, et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012;64:269-272.
12. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1∗11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012;64:1233-1237.
13. Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012;64:4087-4093.
14. Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 2014;93:150-157.